Population 

44 adolescents and adults aged 12 to 39 participated in a 2-month clinical study. 

Application of KERACNYL Body Spray

2 applications per day (morning and evening) on the body (back, chest, and shoulders).

Evaluation Criteria 

• Dermatological evaluation
• Count of acne lesions (retentional and inflammatory lesions)
• Assessment of the volume, diameter, and erythema of acne lesions
• Assessment of acne severity using the TRASS scale
• Subject assessment of overall improvement in acne
• Assessment by the investigator and the subject of the product’s overall efficacy on post-inflammatory erythema and hyperpigmentation
• Instrumental assessment of post-inflammatory erythema and hyperpigmentation
• Assessment of tolerability as monotherapy or in combination with oral antibiotics and anti-acne treatments 

Results

• Significantly reduces inflammatory and retention lesions, erythema, and post-inflammatory marks in 2 days
• -70% reduction in inflammatory lesions in 2 months
• -42% reduction in overall acne in 2 months
• -66% reduction in post-inflammatory hyperpigmentation in 2 months  
• Very well tolerated as monotherapy or in combination with oral antibiotics and acne treatments

Conclusion 

The efficacy and safety results for the KERACNYL body spray, which contains myrtacin and celastrol combined with glycolic and salicylic exfoliating agents, highlight the potential benefits of this product for adolescents and adults with mild to moderate trunk acne.